Poster presentations at ISPOR EU 2023

With more than 40 abstracts accepted, Parexel’s experts, including in partnership with our clients, present posters featuring a range of research and outcomes that impact innovation, value and healthcare decision-making. 
View Parexel’s posters below and connect with our authors to find out more. 

Landscaping for product positioning

Landscape Analysis of Alzheimer's Disease-Specific Caregiver Outcome Assessments 

Economic Burden of SLE in Nordic Countries - a Systematic Literature Review (SLR)

Is our evidence enough? – A review of G-BA´s ongoing evidentiary requirements in the oncology space

Are all unmet needs worth the same when financing health? A review of HTA disease prioritization in Europe

Efficacy of Anti-Alzheimer’S (AD) Drugs in Cognitive Improvement: A Network Meta-Analysis (NMA) of Randomized Controlled Trials (RCTS)

Evolving trends in joint assessments and/or collaborations across HTAs

Top 5% Finalist | Bridging the gap between national and EUnetHTA21 HTA methods. Are marketing authorization holders ready for joint clinical assessments?

Are we leaving no one behind? – Health technology assessment as a pathway to social justice

Long-term impact of new health policy initiatives on reimbursement and coverage

How Will Recent Pricing Regulations Impact the Global Pricing Landscape?

Are Digital Health Therapeutics Reshaping the HTA Framework for Health Technologies?

Impact of TCET legislation on break-through designated devices

A conceptual modeling framework for manufacturers to navigate the Inflation Reduction Act and to negotiate a “fair maximum price”

HTA guidance updates and usage of Real-World Evidence (RWE) in reimbursement decisions - A 2023 perspective

Is the Paradigm Shifting? The REvalMED Pilot Program and Subsequent Integration of Economic Evaluations to Influence Pricing and Reimbursement Discussions in Spain 

Is There Equity of Access to Highly Specialised Treatments between England and Northern Ireland?


Communication of clinical, economic, and real-world evidentiary differentiators

Overview of COA Measures in SLE Clinical Trials and Label Claims

Non-Communicable Diseases Prevention in India: A Review of Suitable Instruments for Surveillance and a General Overview of Cultural, Behavioral Practices and Risk Factors for the Adult Population. 

A Systematic Review of the Use of Registry-Based Randomized Controlled Trials (R-RCTs) for Regulatory Approval and Access 

Implement a Direct-to-Patient Application to Recruit Diverse Patients and Collect Real-World Data

Cost-effectiveness analysis of nivolumab plus relatlimab versus nivolumab monotherapy for patients with advanced melanoma in The Netherlands

Multinational Real-World Data in Transplant Patients with Refractory/Resistant Cytomegalovirus Infection Enhance Cost-Effectiveness Modelling Outcomes 

Real-World Evidence in Post-Authorization Studies: Review of European Databases in the ENCePP EU Pas Register® Between 2010 – 2023

Novel data analytics approaches to value demonstration

Tip for Excel(lent) modelling - or R there better alternatives?

Formulating Bayesian Poly-Hazard Models for Informed and Clinically Interpretable Lifetime Survival Extrapolations in Advanced Non-Small Cell Lung Cancer (aNSCLC)

It's Alive! Feasibility and Benefits of Living Cost-Effectiveness Modeling Following a Living SLR 

Radiographic progression free survival as surrogate endpoint for overall survival among men with Metastatic Castration-Resistant Prostate Cancer

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Other First-Line Therapies for Patients with Stage IV or Recurrent Non-Small Cell Lung Cancer in the United States 

Looking sharp! Applying cutting-edge Shapley Additive explanation (SHAP) approaches to cost-effectiveness modelling in contrast to one-way sensitivity analysis 

Geographic search filters for interface: an analysis utilizing multiple case studies

Inferring the proportion of durable responders to targeted oncology therapies in combination regimens using Bayesian parametric mixture survival models

Extending Bayesian Evidence Synthesis to Include Historical Trial Data for Improved Survival Extrapolations from Early Data Cuts in Metastatic Non-Small Cell Lung Cancer (mNSCLC)


Navigating and leveraging AI for optimized patient access

Long COVID Symptom Diary: Development of a PRO Instrument to Support Drug Development and Regulatory Submissions in Europe

The Use of Copilot, a Generative Artificial Intelligence Tool, as VBA Programming Assistant in Excel-Based Health Economic Models 

Do health technology assessment (HTA) bodies recommend the conduct and submission of artificial intelligence-based literature reviews (AILRs)?

Advancing Causal Inference With Machine Learning and Real-World Data: An Application of Targeted Machine Learning and Super Learners on Hospital-Acquired Pressure Injuries From MIMIC IV 

Causal Machine Learning for Assessing Pneumococcal Vaccine Effectiveness: Innovations in Real-World Data Analysis and Confounding Pathway Adjustment 


Use of patient-centric approaches in clinical trials and drug development and evaluation of treatments

A Review of Migraine-Related Pros in FDA Labelling Claims (2018-2023)

Increasing patient access in Scandinavia through Outcome Based Agreements: Can the Spanish model be replicated?

Survey Research Using PRO Data in Clinical Practice: Lessons Learnt from the Nordic Countries

Integration of Clinical Outcome Assessments (COA) in Drug Approval Process to Foster Patient-Centric Clinical Trials: A Review of 3 Regulatory Guidelines for Drug Development in the APAC

Comparing UK value sets and mapping functions for EQ-5D

A Review of Patient-Reported Outcomes and External Control Arms in Regulatory Submissions of Novel Oncology Drugs

Incorporating Patient Perspectives in HTA Assessments for Rare Diseases: Insights From Multiple HTA Assessments